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Background
Development of safe and efficient vectors is crucial for
gene therapy and vaccine delivery. As a promising trans-
fection reagent, poly [2-(N,N-dimethylamino) ethyl
methacrylate] (PDMAEMA) have potential applications in
gene delivery systems. However, its high cytotoxicity lim-
its its advances into clinical evaluation. Polyethylene gly-
col (PEG) is one of the most widely used to decrease
polymers' cytotoxicity in drug delivery systems. But the
vaccine delivery effects was still unclear by PEGylation for
this polymer.
Methods
PEGylated PDMAEMA was synthesized with PEG seg-
ments by atom transfer radical polymerization, and its
binding capability to DNA was determinded by gel elec-
trophore retardation assaysis. Its effects on transfection
efficiency and cytotoxicity in vitro were determined by
Flow Cytometry using GFP as a reporter and MTT assay
respectivly. Finally, ELISA and Elispot assay were used to
evaluated its effects on immunogenicity as a mucosal
DNA vaccine carrier in vivo. An plasmid DNA expressing
HIV-1 gag was used as an model vaccine.
Results
PEGylated PDMAEMA retained its DNA bing capability
and its cytotoxicity was dramatically decreased compared
to unPEGylated PDMAEMA but with low transfection effi-
ciency  in vitro. However, our in vivo data proved that
PEGylated PDMAEMA significantly improved the priming
effect of an HIV DNA vaccine through intranasal adminis-
tration compared to another cation vector polyethylene-
imine (PEI) and had more immunositmulatory ability in
vitro.
Conclusion
Our study suggested that PEGylated PDMAEMA could be
used in vaccine research as a nonviral vector and impor-
tantly, transfection efficiency in vitro did not correlate to
the immunogenicity in vivo for polymer vectors especially
due to its potential adjuvant effects.
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